Humira denials in California external review
In the California DMHC record, independent physician reviewers decided 51 published external-review cases involving Humiraand overturned the plan’s denial in 72.5%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
Conditions behind Humira denials
| Category | Decisions | Overturned |
|---|---|---|
| Crohn's Disease | 11 | 90.9% |
| Psoriatic Arthritis | 8 | 87.5% |
| Rheumatoid Arthritis | 5 | 60% |
| Ankylosing Spondylitis | 3 | 66.7% |
| Plaque Psoriasis | 3 | 66.7% |
| Psoriasis | 3 | 66.7% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 42 | 73.8% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 9 | 66.7% |
What the reviewers wrote
Where the denial was overturned
Findings: The physician reviewer found that An enrollee has requested authorization and coverage for Humira (adalimumab) subcutaneous injection administered as 1-80 mg injection on day one, followed by 1-40 mg injection on day eight, then 1-40 mg subcutaneous injection administered every two weeks thereafter. Generalized granuloma annulare is a rare disorder that usually becomes chronic. It is difficult to treat as there are no well controlled studies that demonstrate clinical efficacy, and no medications that are approved by the U.S. Food and Drug Administration (FDA) for treatment of this condition. The mainstay of treatment consists of Plaquenil, dapsone, or isotretinoin, and sometimes ultraviolet (UV) light therapy. However, no standard treatment has proven safe and effective. Recently, the TNF alpha inhibitor, Humira, has been used with some success.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Humira pen (adalimumab pen injector kit 40 mg/0.8 ml). Findings: The physician reviewer found that there is sufficient support in the medical literature for the requested medication in this clinical setting. The 2015 European League Against Rheumatism (EULAR) guidelines for the treatment of psoriatic arthritis (PsA) state that with regards to PsA, “The first biologic disease-modifying antirheumatic drug (bDMARD) would usually be a tumour necrosis factor (TNF) inhibitor; bDMARDs targeting interleukin (IL)12/23 (ustekinumab) or IL-17 pathways (secukinumab) may be used in patients for whom TNF inhibitors are inappropriate and a tsDMARD such as a phosphodiesterase 4-inhibitor (apremilast) if bDMARDs are inappropriate.
Where the denial was upheld
Physician 1: The patient is a 23-year-old female who has experienced repeated early pregnancy losses and then underwent evaluation and treatment for recurrent loss. Evaluation included a borderline positive ANA, no evidence of thyroid antibodies, no immune reaction to her partner’s antigens and heterozygosity of MTHFR. There is no evidence the patient was tested for Factor V Leiden mutation, prothrombin gene mutation, lupus anticoagulant, or anticardiolipin antibodies (ACA).The patient was treated with IVIG, Humira, Lovenox, and low dose aspirin for her most recent pregnancy, which was carried to term.Review of the submitted clinical information reveals no documentation of significant autoimmune disease or thrombophilia. The low positive ANA (which was intermittently negative) does not cause pregnancy loss or require treatment.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The parent of a patient has requested authorization and coverage for Humira injection. In regard to oligoarticular juvenile idiopathic arthritis (JIA), patients with more significant disease who do not respond to initial joint injection therapy, or those with initial severe disease activity and poor prognosis risk factors, require treatment with methotrexate or other disease-modifying antirheumatic drugs (DMARDs). Biologic agents (tumor necrosis factor (TNF) inhibitors) are used in patients with severe disease, or moderate disease and poor prognostic features, who do not respond to nonbiologic DMARD therapy. TNF inhibitors are also used in patients with extended oligoarticular JIA and in those with uveitis.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
Why plans deny Humira — and what reviewed cases show
Humira (adalimumab) is FDA-approved for: crohn's disease (adults and children 6 and older); ulcerative colitis (adults and children 5 and older); rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. An on-label indication can be important evidence when a denial frames the requested use as unproven or cosmetic.
Forced switch to a biosimilar
Adalimumab now has many FDA-approved biosimilars, and formularies increasingly cover only their preferred version. The denial isn't a judgment that adalimumab is wrong for you — it's a contracting decision about which adalimumab. If you're stable on brand Humira, the question the exception process weighs is whether switching risks your remission, and that's your prescriber's call to document.
Step therapy — “try conventional therapy first”
For Crohn's and colitis, plans commonly require documented failure of conventional agents (aminosalicylates, corticosteroids, immunomodulators) before covering a biologic. Denials usually cite missing documentation of those trials, not a clinical dispute — the trials happened, but never made it into the prior-auth request.
Continuation denied after a plan or formulary change
New plan year, new employer, or a formulary shuffle can un-approve therapy that has kept you in remission for years. Continuity-of-care arguments are strongest exactly here: the plan needs a clinical reason to interrupt working treatment, and “our contract changed” is not one.
Dose and interval limits
IBD dosing sometimes needs intensification your gastroenterologist prescribes based on response and drug levels. Quantity-limit denials treat that as excess supply. The prescriber's rationale — disease activity, drug-level monitoring, prior response — is what the exception process exists to consider.
Step-therapy and forced-switch requirements yield to a documented exception: your prescriber attests to prior failures, contraindications, or clinical reasons this specific agent is appropriate. Pharmacy exception processes run on deadlines measured in hours to days once that supporting statement is in.
Evidence cited in overturned Humira decisions
- Anchor to the diagnosis and disease severity the chart documents — Crohn's disease and ulcerative colitis are FDA-approved indications, not off-label uses.
- List every conventional agent tried, with dates, doses, and outcomes — that paragraph alone defeats most step-therapy denials.
- If you're stable on current therapy, make remission the centerpiece: describe what uncontrolled disease looked like and have your prescriber state the clinical risk of switching or interrupting.
- Demand the specific criteria document and the exact formulary language the denial relied on.
The published California record contains 51 external-review decisions involving Humira; 72.5% were overturned. This historical rate does not predict another case. For the full class-wide picture — step therapy, biosimilar switching, dose caps, and the record for every IBD biologic — see the Crohn’s & colitis biologic appeal guide.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Humira, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY